{"id":"exenatide-and-sitagliptin","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea"},{"rate":"5-15","effect":"Vomiting"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Hypoglycemia"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Exenatide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, promoting insulin secretion in response to elevated blood glucose and slowing gastric emptying. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prevents the degradation of endogenous incretin hormones (GLP-1 and GIP), thereby extending their glucose-lowering effects. Together, they provide synergistic glycemic control in type 2 diabetes.","oneSentence":"This combination drug stimulates insulin secretion through two complementary pathways: exenatide activates GLP-1 receptors to enhance glucose-dependent insulin release, while sitagliptin inhibits DPP-4 to prolong the action of endogenous GLP-1 and GIP.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:05.748Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT00775684","phase":"NA","title":"Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-10","conditions":"Pre-diabetes, Type 2 Diabetes","enrollment":47},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT01235819","phase":"PHASE4","title":"Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Command Hospital, India","startDate":"2010-11","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT01455870","phase":"PHASE3","title":"A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"Intarcia Therapeutics","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":535},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT01744236","phase":"PHASE4","title":"SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-04","conditions":"Type 2 Diabetes","enrollment":70},{"nctId":"NCT00806520","phase":"","title":"Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT00477581","phase":"PHASE4","title":"A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Type 2 Diabetes Mellitus","enrollment":102},{"nctId":"NCT01652729","phase":"PHASE3","title":"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-02","conditions":"Diabetes Type 2","enrollment":365},{"nctId":"NCT01077323","phase":"","title":"A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)","enrollment":363766},{"nctId":"NCT00676338","phase":"PHASE3","title":"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Type 2 Diabetes Mellitus","enrollment":820},{"nctId":"NCT00729326","phase":"PHASE4","title":"Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-08","conditions":"Type 2 Diabetes Mellitus","enrollment":83},{"nctId":"NCT00870194","phase":"PHASE4","title":"A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Type 2 Diabetes Mellitus","enrollment":255},{"nctId":"NCT00637273","phase":"PHASE3","title":"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT01767389","phase":"","title":"Glucagon-like Peptide (GLP) Utilization and Safety","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1},{"nctId":"NCT01455909","phase":"PHASE3","title":"A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Intarcia Therapeutics","startDate":"2013-02","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT00971659","phase":"PHASE1","title":"Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["exenatide-Byetta; sitagliptin-Januvia"],"phase":"marketed","status":"active","brandName":"exenatide and sitagliptin","genericName":"exenatide and sitagliptin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug stimulates insulin secretion through two complementary pathways: exenatide activates GLP-1 receptors to enhance glucose-dependent insulin release, while sitagliptin inhibits DPP-4 to prolong the action of endogenous GLP-1 and GIP. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}